DRUGS FOR PHOTODYNAMIC THERAPY

光动力治疗药物

• 批准号: 7355170
• 负责人: MALCOLM E KENNEY
• 金额: $ 0.08万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-01 至 2007-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7355170
• 关键词: DRUGS; PHOTODYNAMIC; THERAPY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Compounds of the phthalocyanine and napthalocyanine types are being synthesized and characterized for use in a cooperative research program on photodynamic therapy. The work is focused on the synthesis of compounds that have the desired light absorption, solubility, polarity, and stability. The compounds made are characterized by spectroscopy and then used in collaborative cell and animal studies. The work has resulted in a drug, Pc 4, which has been approved for use in Phase 1 human clinical trials with cancer patients

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。酞菁和萘酞菁类型的化合物正在合成和表征中用于光动力疗法的合作研究计划。这项工作的重点是合成具有所需光吸收，溶解性，极性和稳定性的化合物。所制备的化合物通过光谱学进行表征，然后用于协同细胞和动物研究。这项工作已经产生了一种名为Pc 4的药物，该药物已被批准用于癌症患者的第一阶段人体临床试验